Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

1.

T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.

Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, Livingston PO, Williams L, Lewis JJ, Houghton AN, Chapman PB.

Clin Cancer Res. 2002 May;8(5):967-72.

PMID:
12006508
[PubMed - indexed for MEDLINE]
Free Article
2.

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.

Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP.

Cancer. 2003 Jan 1;97(1):186-200.

PMID:
12491520
[PubMed - indexed for MEDLINE]
Free Article
3.

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.

Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH.

J Clin Oncol. 2003 Nov 1;21(21):4016-26.

PMID:
14581425
[PubMed - indexed for MEDLINE]
Free Article
4.

Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide.

Lewis JJ, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, Meyers M, Butterworth L, Livingston PO, Chapman PB, Houghton AN.

Int J Cancer. 2000 Aug 1;87(3):391-8.

PMID:
10897045
[PubMed - indexed for MEDLINE]
5.

Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.

Valmori D, Dutoit V, Ayyoub M, Rimoldi D, Guillaume P, Liénard D, Lejeune F, Cerottini JC, Romero P, Speiser DE.

Cancer Immun. 2003 Oct 28;3:15.

PMID:
14580186
[PubMed - indexed for MEDLINE]
Free Article
6.

Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.

Smith JW 2nd, Walker EB, Fox BA, Haley D, Wisner KP, Doran T, Fisher B, Justice L, Wood W, Vetto J, Maecker H, Dols A, Meijer S, Hu HM, Romero P, Alvord WG, Urba WJ.

J Clin Oncol. 2003 Apr 15;21(8):1562-73.

PMID:
12697882
[PubMed - indexed for MEDLINE]
Free Article
7.

Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.

Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J.

Clin Cancer Res. 1999 Oct;5(10):2756-65.

PMID:
10537339
[PubMed - indexed for MEDLINE]
Free Article
8.

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA.

Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23.

PMID:
9815296
[PubMed - indexed for MEDLINE]
9.

Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.

Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y, Gooding WE, Kirkwood JM.

J Immunother. 2012 May;35(4):359-66. doi: 10.1097/CJI.0b013e31825481fe. Erratum in: J Immunother. 2012 Oct;35(8):650.

PMID:
22495394
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides.

Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, Letsch A, Philipp A, Foerster MH, Schmittel A, Thiel E, Keilholz U.

Int J Cancer. 2003 Mar 20;104(2):188-94.

PMID:
12569574
[PubMed - indexed for MEDLINE]
11.

A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.

Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS.

Clin Cancer Res. 2003 Apr;9(4):1301-12.

PMID:
12684398
[PubMed - indexed for MEDLINE]
Free Article
12.

Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.

Markovic SN, Suman VJ, Ingle JN, Kaur JS, Pitot HC, Loprinzi CL, Rao RD, Creagan ET, Pittelkow MR, Allred JB, Nevala WK, Celis E.

Am J Clin Oncol. 2006 Aug;29(4):352-60.

PMID:
16891861
[PubMed - indexed for MEDLINE]
13.

Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.

Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC.

J Clin Oncol. 2005 Dec 10;23(35):8978-91. Epub 2005 Oct 31.

PMID:
16260696
[PubMed - indexed for MEDLINE]
Free Article
14.

Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

Knutson KL, Schiffman K, Cheever MA, Disis ML.

Clin Cancer Res. 2002 May;8(5):1014-8.

PMID:
12006513
[PubMed - indexed for MEDLINE]
Free Article
15.

T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.

Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA.

Cancer J. 2000 Mar-Apr;6(2):69-77.

PMID:
11069222
[PubMed - indexed for MEDLINE]
16.

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P.

J Clin Invest. 2005 Mar;115(3):739-46.

PMID:
15696196
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma.

Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J.

J Clin Oncol. 2001 Sep 15;19(18):3836-47.

PMID:
11559721
[PubMed - indexed for MEDLINE]
Free Article
18.

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.

Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchianò A, Santantonio C, Tosi D, Arienti F, Cova A, Sovena G, Piris A, Nonaka D, Bersani I, Di Florio A, Luigi M, Srivastava PK, Hoos A, Santinami M, Parmiani G.

Cancer Immunol Immunother. 2006 Aug;55(8):958-68. Epub 2005 Oct 8.

PMID:
16215718
[PubMed - indexed for MEDLINE]
19.

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.

Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, Del Vecchio M, Ravagnani F, Magni M, Chaplin P, Cascinelli N, Parmiani G, Gianni AM, Anichini A.

Clin Cancer Res. 2004 Aug 15;10(16):5381-90.

PMID:
15328176
[PubMed - indexed for MEDLINE]
Free Article
20.

MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.

Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, Petroni GR, Bissonette EA, Neese PY, Grosh WW, Merrill P, Fink R, Woodson EM, Wiernasz CJ, Patterson JW, Slingluff CL Jr.

J Immunol. 2005 Mar 1;174(5):3080-6.

PMID:
15728523
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk